Fig. 7: T-αFGL2 treatment increased the CD69⁺CD8⁺T_M cell subset.

a Schematic of the experimental design. Four days after the second infusion of T-Ctr or T-αFGL2 cells, brains were collected to isolate brain-infiltrating lymphocytes (BILs), which were then stained with antibodies conjugated to metal isotopes. Single-cell mass cytometry (CyTOF) data were clustered to identify common populations across the treatment groups (n = 4 mice per group). The experiment was carried out once. b Analysis of CD45⁺ cells from the brain, colored by relative expression of CyTOF markers. Cell populations are indicated on the right. c Frequencies of total CD8⁺ T cell population and subsets of CD8⁺ T cells and CD4⁺ T cells (n = 4 mice per group; data represent mean ± SD), two-tailed t-test. d Composition of the CD8⁺ T cell compartment in T-Ctr and T-αFGL2-treated DBT-bearing mice showing increased frequency of CD69⁺CD8⁺ T_M cells in the T-αFGL2 group. e, Fold expression of Ki67, CD69, CD223, and CD279 on the CD69⁺CD8⁺T_M subset and the CD69⁻CD8⁺T_EM subset. f Schematic of experimental design. On day 1, 3 × 10⁴ CD8⁺ T_RM cells and 3 × 10³ DBT cells were coinoculated i.c. into naïve Balb/c mice; on days 0, 5, 10, 15, and 20, the mice were treated with either IgG or CD69 blocking antibodies (150 μg/mouse, i.p.); on day 60, Balb/c mice bearing transplanted CD8⁺T_RM were rechallenged with 1 × 10⁴ DBT cells (i.c.). g Representative bioluminescence images of Balb/c mice on days 0 and 7 after i.c. rechallenge with DBT cells in (f). Data are representative of two independent experiments. h Kaplan–Meier survival curves of mice in (f) (n = 3 mice/group), log-rank test. The experiments were carried out twice with similar results.